Gross Margin % is calculated as gross profit divided by its revenue. Myovant Sciences's Gross Profit for the
three
months ended in Mar. 2022 was $39.8 Mil. Myovant Sciences's Revenue for the
three
months ended in Mar. 2022 was $57.6 Mil. Therefore, Myovant Sciences's Gross Margin % for the quarter that ended in Mar. 2022 was 69.18%.
The historical rank and industry rank for Myovant Sciences's Gross Margin % or its related term are showing as below:
MYOV'
s Gross Margin % Range Over the Past 10 Years
Min: 77.68 Med: 87.19 Max: 96.69
Current: 77.68
During the past 7 years, the highestGross Margin % of Myovant Sciences was 96.69%. The lowest was 77.68%. And the median was 87.19%.
MYOV's Gross Margin % is ranked better than 68.66% of 718
companies
in the Biotechnology industry
Industry Median: 61.23
vs MYOV: 77.68
Myovant Sciences had a gross margin of 69.18% for the quarter that ended in Mar. 2022 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Myovant Sciences was 0.00% per year.
Myovant Sciences Gross Margin % Historical Data
The historical data trend for Myovant Sciences's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Myovant Sciences Annual Data
Trend
Mar16
Mar17
Mar18
Mar19
Mar20
Mar21
Mar22
Gross Margin %
-
-
-
96.69
77.68
Myovant Sciences Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Gross Margin %
92.01
84.67
85.64
70.01
69.18
Competitive Comparison
For the Biotechnology subindustry, Myovant Sciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myovant Sciences Gross Margin % Distribution
For the Biotechnology industry and Healthcare sector, Myovant Sciences's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Myovant Sciences's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Myovant Sciences had a gross margin of 69.18% for the quarter that ended in Mar. 2022 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Myovant Sciences Gross Margin % Related Terms
Thank you for viewing the detailed overview of Myovant Sciences's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.41(4.07%) Volume: 491,528 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NYSE:MYOV has been successfully added to your 
